BG60250B1 - Метод за получаване на тумор некрозис фактор - Google Patents

Метод за получаване на тумор некрозис фактор

Info

Publication number
BG60250B1
BG60250B1 BG070958A BG7095885A BG60250B1 BG 60250 B1 BG60250 B1 BG 60250B1 BG 070958 A BG070958 A BG 070958A BG 7095885 A BG7095885 A BG 7095885A BG 60250 B1 BG60250 B1 BG 60250B1
Authority
BG
Bulgaria
Prior art keywords
necrosis factor
tumor necrosis
tnf
purifies
cells
Prior art date
Application number
BG070958A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG60250B2 (bg
Inventor
Bharat Aggarwal
David Goeddel
Sang Lee
Glenn Nedwin
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/677,257 external-priority patent/US4650674A/en
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of BG60250B1 publication Critical patent/BG60250B1/bg
Publication of BG60250B2 publication Critical patent/BG60250B2/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BG70958A 1984-07-05 1985-07-04 Метод за получаване на тумор некрозис фактор BG60250B2 (bg)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US62806084A 1984-07-05 1984-07-05
US62795984A 1984-07-05 1984-07-05
US62805984A 1984-07-05 1984-07-05
US67745484A 1984-12-03 1984-12-03
US67715684A 1984-12-03 1984-12-03
US06/677,257 US4650674A (en) 1984-07-05 1984-12-03 Synergistic cytotoxic composition

Publications (2)

Publication Number Publication Date
BG60250B1 true BG60250B1 (bg) 1994-03-24
BG60250B2 BG60250B2 (bg) 1994-03-24

Family

ID=27560190

Family Applications (1)

Application Number Title Priority Date Filing Date
BG70958A BG60250B2 (bg) 1984-07-05 1985-07-04 Метод за получаване на тумор некрозис фактор

Country Status (20)

Country Link
EP (1) EP0168214B1 (enExample)
JP (4) JP2557341B2 (enExample)
AT (1) ATE113295T1 (enExample)
AU (1) AU599571B2 (enExample)
BG (1) BG60250B2 (enExample)
CZ (1) CZ283149B6 (enExample)
DE (2) DE19975064I2 (enExample)
DK (2) DK169894B1 (enExample)
FI (2) FI95472C (enExample)
GR (1) GR851626B (enExample)
HU (1) HU209153B (enExample)
IE (1) IE65426B1 (enExample)
IL (2) IL75717A (enExample)
LU (1) LU90456I2 (enExample)
NL (1) NL990033I2 (enExample)
NO (1) NO852673L (enExample)
NZ (1) NZ212632A (enExample)
PL (1) PL155778B1 (enExample)
SK (1) SK279897B6 (enExample)
YU (1) YU47968B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
DE3582183D1 (de) * 1984-03-06 1991-04-25 Dainippon Pharmaceutical Co Dns den menschlichen tumornekrosisfaktor kodierend und das menschliche tumornekronisfaktor-polypeptid.
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
JP2675294B2 (ja) * 1984-10-15 1997-11-12 カイロン コーポレイション ヒト腫瘍壊死因子
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
ATE73856T1 (de) * 1984-12-21 1992-04-15 Biogen Inc Reinigung, herstellung und verwendung von tumor- nekrosisfaktoren.
JPS61155330A (ja) * 1984-12-28 1986-07-15 Denichi Mizuno 蛋白質標品
JPS6248634A (ja) * 1985-07-23 1987-03-03 Mochida Pharmaceut Co Ltd 新規アミノ酸組成物、その製造方法及び該アミノ酸組成物を含有する医療組成物
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
CA1340998C (en) * 1986-02-04 2000-05-23 Den'ichi Mizuno Dnas and processes for their preparation, novel plasmids possessing them, novel polypeptides and processes for their preparation and novel anti-tumor agents comprising said polypeptides
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
PT85076B (pt) * 1986-06-16 1990-07-31 Genentech Inc Metodo para o tratamento de doencas infecciosas pela administracao de factor de necrose tumoral-alfa
JPH0817712B2 (ja) * 1986-06-20 1996-02-28 大日本製薬株式会社 新規ヒトｔｎｆポリペプチド変異体
DE3750056T2 (de) * 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
US4857314A (en) * 1986-07-18 1989-08-15 Health Research , Inc. C-reactive proteins in treatment of animal and human cancers
CA1340698C (en) * 1986-07-25 1999-08-10 Kabushiki Kaisha Hayashibara Seibutsu Kaguku Kenkyujo Preparation and uses of interferon-gamma
KR880001300A (ko) * 1986-07-31 1988-04-22 맥스 디. 헨슬리 리트로바이러스 감염의 예방 및 치료를 위한 방법 및 조성물
US5002876A (en) * 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US4777242A (en) * 1986-10-10 1988-10-11 Phillips Petroleum Company Purification of recombinant tumor necrosis factor
WO1988006625A2 (en) * 1987-02-26 1988-09-07 Cetus Corporation Arginine-depleted human tumor necrosis factor
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
JPS6463395A (en) * 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
DE3837012A1 (de) * 1988-01-15 1989-07-27 Knoll Ag Verwendung von tnf und lt zur herstellung von arzneimitteln
GB2217325B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene for tumour necrosis factor alpha.
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
EP0491878B1 (en) 1989-08-16 1997-02-19 Chiron Corporation Compositions for the inhibition of protein hormone formation and uses thereof
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
EP0519976B1 (en) * 1990-03-12 1997-02-26 Peptide Technology Ltd Neutrophil stimulating peptides
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
CA2055168A1 (en) * 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
AU6001094A (en) * 1993-02-03 1994-08-29 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
KR970005042B1 (ko) * 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
EP0749494A1 (en) 1994-03-07 1996-12-27 Chiron Corporation Compositions for the inhibition of tnf formation and uses thereof
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
IL120979A0 (en) * 1997-06-02 1997-11-20 Interpharm Lab Ltd Glycosylated TNF
PT2953634T (pt) 2013-02-07 2021-09-02 Massachusetts Gen Hospital Métodos de expansão ou depleção das células t reguladoras

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH65623A (de) * 1913-08-02 1914-07-01 Siemens Ag Zeitrelais mit Wechselstrommotor und dessen Drehmoment entgegenwirkender Feder
NO163060C (no) * 1981-03-13 1990-03-28 Damon Biotech Inc Fremgangsmaate for fremstilling av substanser som dannes av levende celler som produserer interferoner eller antistoffer.
JPS5821621A (ja) * 1981-07-31 1983-02-08 Hayashibara Biochem Lab Inc ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
JPS60226816A (ja) * 1984-11-16 1985-11-12 Asahi Chem Ind Co Ltd 抗腫瘍活性をもつヒト由来蛋白質
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
JPS60166696A (ja) * 1984-02-08 1985-08-29 Asahi Chem Ind Co Ltd 新規生理活性ポリペプチドのｄνａ
JPS60137292A (ja) * 1983-12-26 1985-07-20 Asahi Chem Ind Co Ltd 新規生理活性ポリペプチドの遺伝情報を有するポリデオキシリボ核酸、該ポリデオキシリボ核酸を含む複製可能な組換ｄνａ、該複製可能な組換ｄνａで形質転換された微生物または細胞、新規生理活性ポリペプチド及びその製造方法
DE3472793D1 (en) * 1983-12-26 1988-08-25 Asahi Chemical Ind A novel physiologically active polypeptide
JPS60221092A (ja) * 1984-04-18 1985-11-05 Asahi Chem Ind Co Ltd 新規生理活性ポリペプチドのｄｎａ
JPS60232097A (ja) * 1984-04-23 1985-11-18 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子ポリペプチドの製造法
JPS60185799A (ja) * 1984-03-06 1985-09-21 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子
DE3582183D1 (de) * 1984-03-06 1991-04-25 Dainippon Pharmaceutical Co Dns den menschlichen tumornekrosisfaktor kodierend und das menschliche tumornekronisfaktor-polypeptid.
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
DE3421731A1 (de) * 1984-06-12 1985-12-12 Boehringer Ingelheim International GmbH, 6507 Ingelheim Humaner-tumor-nekrose-faktor
JP2675294B2 (ja) * 1984-10-15 1997-11-12 カイロン コーポレイション ヒト腫瘍壊死因子
JP2515975B2 (ja) * 1985-02-26 1996-07-10 大日本製薬株式会社 抗腫瘍作用を有するポリペプチド

Also Published As

Publication number Publication date
AU599571B2 (en) 1990-07-26
EP0168214A2 (en) 1986-01-15
HUT38125A (en) 1986-04-28
JP2557341B2 (ja) 1996-11-27
DE19975064I2 (de) 2005-11-03
PL254399A1 (en) 1986-06-17
PL155778B1 (pl) 1992-01-31
FI95472C (fi) 1996-02-12
GR851626B (enExample) 1985-11-26
JPH07291997A (ja) 1995-11-07
FI98217B (fi) 1997-01-31
BG60250B2 (bg) 1994-03-24
NL990033I1 (nl) 1999-12-01
DE3587939T2 (de) 1995-04-27
NL990033I2 (nl) 2000-11-01
DK169894B1 (da) 1995-03-27
DK305885A (da) 1986-03-14
DE19975064I1 (de) 2005-09-29
CZ506785A3 (en) 1997-07-16
FI98217C (fi) 1997-05-12
JPH083061A (ja) 1996-01-09
YU113285A (en) 1991-04-30
JPS6140221A (ja) 1986-02-26
NO852673L (no) 1986-01-06
IL75717A (en) 1994-11-28
AU4465285A (en) 1986-01-09
SK506785A3 (en) 1999-05-07
CZ283149B6 (cs) 1998-01-14
FI852626A0 (fi) 1985-07-03
ATE113295T1 (de) 1994-11-15
JP2614989B2 (ja) 1997-05-28
DK75694A (da) 1994-06-24
FI852626L (fi) 1986-01-06
DK305885D0 (da) 1985-07-04
SK279897B6 (sk) 1999-05-07
IE851691L (en) 1986-01-05
FI943750L (fi) 1994-08-15
FI943750A0 (fi) 1994-08-15
EP0168214B1 (en) 1994-10-26
NZ212632A (en) 1991-05-28
DK171418B1 (da) 1996-10-21
YU47968B (sh) 1996-08-13
JPH0928387A (ja) 1997-02-04
IE65426B1 (en) 1995-11-01
HU209153B (en) 1994-03-28
EP0168214A3 (en) 1987-12-16
IL75717A0 (en) 1985-11-29
LU90456I2 (fr) 1999-12-06
FI95472B (fi) 1995-10-31
IL105271A (en) 1995-07-31
DE3587939D1 (de) 1994-12-01

Similar Documents

Publication Publication Date Title
BG60250B1 (bg) Метод за получаване на тумор некрозис фактор
DE3650788D1 (de) Produktion des pluripotenten Granulozyten-Koloniestimulierungsfaktors
ES8600783A1 (es) Procedimiento para la preparacion de la hormona polipeptidica factor de crecimiento de nervios de humano.
MY102546A (en) Human immune interferon
DE3687705D1 (de) Molekulare zuechtung.
FI885679A0 (fi) Samuttryckning i eukariotiska celler.
IL89011A0 (en) Receptor protein,dna sequence coding therefor and process for the preparation thereof
BG60238B1 (bg) Човешки тумор- некротизиращ фактор
NO177270C (no) Fremg. for fremstilling av terapeutisk aktive, humane granulocytt-makrofag-"kolonistimulerende"-faktorproteiner (GM-CSF), bakteriell ekspresjonvektor som er i stand til å uttrykke GM-CSF samt bakteriecelle inneholdende vektoren
CA1341437C (en) METHOD OF USING EUKARYOTIC EXPRESSION VECTORS COMPRISING A BK VIRUS AMPLIFIER
JPS642572A (en) Polypeptide, dna and use thereof
EP0363127A3 (en) Improvements in or relating to eukaryotic expression
JPS6490199A (en) T cell growth factor derived from thymic interstitial cell and production thereof
EP0336383A3 (en) Novel recombinant human lymphotoxin
Smalley et al. Biological response modifiers: preclinical evaluation and clinical activity
HUP9800520A2 (hu) Génexpresszió emlős sejtekben
JPS6437291A (en) Human cytochrome c gene and use thereof
JPS6438099A (en) Fused protein or dihydrofolate reductase and bradykinin
JPS6420083A (en) Preparation of human iga secretory cell
KR880007720A (ko) 유전자 재조합 기술에 의한 사람 알파 인터페론의 제조방법
JPS6437299A (en) Novel physiologically active polypeptide
Vilček et al. Studies with purified human gamma interferon
JPS6485095A (en) Novel physiologically active polypeptide
JPS6485092A (en) Production of protein
ES8801944A1 (es) Procedimiento de preparar substancias activas antitumor